Attovia Therapeutics Inc (Nasdaq: ATTO), a clinical-stage immunology company whose nanobody-based biologics platform has attracted USD 255.8 million in private backing from prominent life sciences investors, filed an S-1 registration statement with the US SEC on July 15, 2026, seeking to list on the Nasdaq Global Market. Pricing terms, share count, and gross proceeds remain redacted in this initial filing.
Attovia, founded in 2023, has raised USD 255.8 million since inception, according to the S-1. Institutional investors holding 5% or greater stakes include Deep Track Capital, Frazier Life Sciences, Goldman Sachs Alternatives, and venBio. Deep Track is a crossover fund active in both private and public biotech markets; its presence as a named pre-IPO holder is a signal investors typically read as supportive of an eventual public offering. No concurrent private placement alongside the IPO was disclosed in this initial filing.
Company background
Attovia was co-founded by Alamar Biosciences Inc, which licensed its ATTOBODY platform to the company as the basis for its therapeutic pipeline. The ATTOBODY platform engineers molecules using paired heavy-chain antibody variable domains, known as VHHs or nanobodies, connected by proprietary linkers in a biparatopic format. The platform is designed to produce monospecific, bispecific, and trispecific biologics with tunable affinity, extended half-life, and manufacturability using standard biologic production processes.
The company's lead asset, ATTO-1310, is a half-life extended IL-31-targeting fusion protein in Phase I development for chronic pruritic diseases, including chronic pruritus of unknown origin, high-itch atopic dermatitis, cholestatic pruritus, and chronic kidney disease-associated pruritus. The S-1 states that Phase I dosing in healthy volunteers and patients was completed in Q1 2026, and that initial data demonstrated favorable tolerability, low immunogenicity, and pharmacokinetic and target engagement profiles consistent with a potential quarterly subcutaneous dosing regimen. The filing states rapid, deep itch relief was observed in patient cohorts.